NEW YORK, Nov. 20, 2017 /PRNewswire/ -- If you want a Stock Review on ISRG, ACRX, GNMK, or LNTH then come over to http://dailystocktracker.com/register/and sign up for your free customized report. DailyStockTracker.com reexplores the Medical Appliances and Equipment space, which comprises companies that are engaged in the manufacture of medical instruments such as dental and surgical appliances. Equities
Sunnyvale, California headquartered Intuitive Surgical Inc.'s stock saw a slight correction of 0.34%, finishing last Friday's trading session at $392.48. A total volume of 617,095 shares was traded. The Company's shares have gained 9.80% in the last month, 19.82% over the previous three months, and 85.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.95% and 28.24%, respectively. Additionally, shares of Intuitive Surgical, which designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories, have a Relative Strength Index (RSI) of 72.15.
On October 20th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $1100 a share to $400 a share. See our free and comprehensive research report on ISRG at: http://dailystocktracker.com/registration/?symbol=ISRG
Shares in Redwood City, California headquartered AcelRx Pharmaceuticals Inc. ended at $2.08, rising 1.22% from the last trading session. The stock recorded a trading volume of 687,350 shares. The Company's shares have advanced 18.57% in the past month. The stock is trading 27.55% below its 200-day moving average. Moreover, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 48.00.
On November 16th, 2017, AcelRx Pharma reported the publication of a manuscript analyzing sufentanil sublingual tablet 30 mcg for postoperative pain in the peer-reviewed journal, "Pain Medicine." Conclusions of the study highlighted that sufentanil sublingual was effective and well-tolerated for the management of moderate-to-severe acute postoperative pain in an older patient population, many with comorbidities, following a variety of surgical procedures, including knee replacement, open-abdominal surgery, and bunionectomy. ACRX free research report is just a click away at: http://dailystocktracker.com/registration/?symbol=ACRX
On Friday, shares in Carlsbad, California headquartered GenMark Diagnostics Inc. recorded a trading volume of 415,855 shares. The stock declined 0.63%, closing the day at $4.77. The Company's shares are trading 40.48% below their 50-day moving average. Additionally, shares of GenMark Diagnostics, which develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology, have an RSI of 27.44.
On November 02nd, 2017, GenMark Diagnostics announced financial results for Q3 ended September 30th, 2017. Revenue was $11.6 million in Q3 2017, operating expenses were $18.9 million, and loss per share was $0.28. The Company ended the quarter with $86.9 million in cash and investments.
On November 03rd, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $15 a share to $11 a share. Sign up for your complimentary report on GNMK at: http://dailystocktracker.com/registration/?symbol=GNMK
At the close of trading on Friday, shares in North Billerica, Massachusetts headquartered Lantheus Holdings Inc. recorded a trading volume of 372,039 shares. The stock finished the session 2.29% higher at $22.35. The Company's shares have surged 28.45% in the past month, 44.19% in the previous three months, and 159.88% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 18.56% and 41.31%, respectively. Furthermore, shares of Lantheus, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, have an RSI of 63.32.
On November 02nd, 2017, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On November 02nd, 2017, Lantheus reported financial results for its Q3 ended September 30th, 2017. Worldwide revenues for Q3 2017 totaled $79.9 million, net income totaled $8.5 million, and adjusted EBITDA was $22.6 million. The Company has also increased its full-year 2017 worldwide revenue guidance range to $323 million to $325 million as well as its full-year 2017 guidance range for adjusted EBITDA to $86 million to $88 million. Register for free on DailyStockTracker.com and download the latest research report on LNTH at: http://dailystocktracker.com/registration/?symbol=LNTH
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South AfricaCFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/breakfast-technical-briefing-on-medical-equipment-stocks----intuitive-surgical-acelrx-pharma-genmark-diagnostics-and-lantheus-300559232.html
Subscribe to our Free Newsletters!
Dental Anxiety is kind of dental phobia where a person has a fear of going to dentist mainly due to ...
Kleine Levin (KLS) or sleeping beauty syndrome is a rare neurological disorder that primarly ...
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...View All